Feline Alimentary Lymphoma (Small Cell / Low-Grade)

Feline alimentary lymphoma (small cell / low-grade), also referred to as low-grade alimentary lymphoma (LGAL) or low-grade intestinal T-cell lymphoma (LGITL), is a neoplastic condition characterized by the diffuse infiltration of well-differentiated, small neoplastic T-lymphocytes predominantly into the mucosa of the small intestine [3]. It is currently the most common gastrointestinal neoplasm in cats, representing 60–75% of all feline gastrointestinal lymphoma cases, and its incidence has risen markedly over the past two decades, coinciding with the decline of feline leukemia virus (FeLV)-associated lymphomas [3][4]. The disease is particularly challenging to manage clinically because its symptoms, laboratory findings, and ultrasonographic appearance overlap substantially with those of inflammatory bowel disease (IBD), specifically lymphoplasmacytic enteritis (LPE), making definitive diagnosis difficult [1][2][5]. LGAL has also been proposed as a potential animal model for analogous human intestinal T-cell lymphomas due to shared biological and clinical features [3].

The precise etiology of feline small cell alimentary lymphoma remains incompletely understood, but multiple contributing factors have been identified or proposed [3][5]:

Cellular Origin and Phenotype LGAL is predominantly a T-cell lymphoma, with neoplastic cells most commonly expressing CD3 and frequently CD8, consistent with cytotoxic T-lymphocyte origin [2][3]. In a smaller proportion of cases, an epitheliotropic pattern is observed, with neoplastic T-cells infiltrating intestinal epithelium, resembling enteropathy-associated T-cell lymphoma (EATL) in humans [3][8]. The neoplastic infiltrate is composed of small, well-differentiated lymphocytes with low mitotic activity, explaining the indolent clinical course [4].

Relationship to Chronic Inflammation A widely debated hypothesis is that LGAL may represent the malignant transformation of chronic intestinal inflammation (inflammatory bowel disease / lymphoplasmacytic enteritis). Chronic antigenic stimulation in the gut may drive persistent clonal T-cell expansion that eventually undergoes malignant transformation [5]. Supporting this, LGAL and LPE share overlapping histologic, immunophenotypic, and clinical features, forming what is increasingly conceptualized as a diagnostic continuum [5].

Microbiome Dysbiosis and Tryptophan Metabolism Emerging evidence suggests that alterations in intestinal microbial communities contribute to disease pathogenesis. Cats with LGITL exhibit significantly altered microbial catabolism of tryptophan, with decreased levels of microbial indole catabolites of tryptophan (MICTs) compared to healthy cats [6]. Since MICTs are known to regulate intestinal mucosal barrier integrity and modulate local immune responses, their deficiency may perpetuate intestinal inflammation and facilitate neoplastic transformation [6].

Serum Proteome Alterations Proteomic analysis has identified alterations in serum protein profiles in cats with chronic enteropathies, including LGAL, reflecting systemic inflammatory responses, dysproteinemia, and altered acute-phase protein production, though specific biomarkers discriminating LGAL from IBD at the proteome level remain under investigation [7].

Risk Factors Middle-aged to older cats are predominantly affected [1][3][4]. No definitive breed, sex, or FeLV-association has been established for the low-grade form, in contrast to the high-grade mediastinal lymphoma historically linked to FeLV. Siamese cats may have a predisposition to intestinal lymphoma more broadly [4].

Diagnosis of feline small cell alimentary lymphoma is multifaceted and requires integration of clinical, laboratory, imaging, histopathologic, immunohistochemical, and molecular findings. No single test is pathognomonic [2][5].

Clinical and Physical Examination Chronic weight loss, vomiting, and diarrhea in an older cat warrant full workup. Palpable intestinal thickening or a midabdominal mass may be found on physical examination [1][4].

Laboratory Findings Routine hematology and biochemistry results in LGAL are often non-specific but can include [1][3][4]:

• ·Hypoalbuminemia (↓ ALB): Reflects protein-losing enteropathy and is one of the more consistently noted abnormalities; significantly lower in LGITL than in LPE in some studies [1]
• ·Hyperglobulinemia (↑ GLOB): May be present, reflecting chronic immune stimulation
• ·Hypocobalaminemia (↓ Vitamin B12 / cobalamin): Common due to small intestinal malabsorption, especially ileal disease; an important supportive finding
• ·Decreased folate: May also be seen with proximal small intestinal involvement
• ·Mild non-regenerative anemia (↓ HCT): Consistent with chronic disease in some patients
• ·Elevated BUN: May be present with prerenal azotemia secondary to protein-losing enteropathy or concurrent chronic kidney disease, common in this age group
• ·ALT elevation: Occasionally noted, may suggest secondary hepatic involvement or concurrent hepatic disease
• ·Lymphopenia or abnormal lymphocyte populations on CBC: Occasionally detected; circulating neoplastic lymphocytes are uncommon in low-grade disease
• ·Low PLT: Less common but may occur

Abdominal Ultrasonography Ultrasound is a critical first-line imaging modality but findings overlap with IBD [1][3]. Features that may suggest LGITL over LPE include:

• ·Diffuse, symmetrical thickening of the muscularis propria layer of the small intestinal wall (muscularis layer prominence) [1][3]
• ·Loss of normal intestinal wall layering
• ·Mesenteric lymphadenopathy (enlarged, hypoechoic mesenteric lymph nodes)
• ·Reduced intestinal motility However, none of these findings alone is diagnostic [1][5].

Endoscopic Biopsy vs. Full-Thickness Surgical Biopsy Endoscopic biopsies are minimally invasive but obtain only superficial mucosal samples, which may be insufficient for definitive diagnosis. Full-thickness surgical biopsies via laparotomy or laparoscopy provide deeper tissue samples including the muscularis propria and are generally preferred for definitive diagnosis [2][5]. Multiple segments should be sampled.

Histopathology Histologically, LGAL is characterized by dense infiltration of small, mature lymphocytes expanding the lamina propria and often extending into the epithelium (epitheliotropism) [2][3]. Villous blunting and crypt distortion may be present. The distinction from LPE on routine H&E staining alone can be extremely difficult [2].

Immunohistochemistry (IHC) IHC is essential. The neoplastic lymphocytes in LGAL are predominantly CD3+ (T-cell marker) with frequent CD8 expression and typically low Ki67 (low proliferative index) [2][3]. Loss of CD5, absence of CD20+ cells as the dominant population, and altered CD4:CD8 ratios support malignancy [2]. IHC is necessary to confirm T-cell lineage and differentiate from B-cell disorders.

Clonality Testing (PCR for Antigen Receptor Rearrangements — PARR) Molecular clonality testing via PARR detects clonal T-cell receptor gene rearrangements, supporting a neoplastic diagnosis. However, clonality results must be interpreted cautiously, as oligoclonal or even clonal expansions can occur in severe inflammatory conditions, and false negatives occur in true lymphoma [2][5]. PARR is most useful when combined with histopathology and IHC [2].

Cytology Fine-needle aspirate cytology of intestinal wall or mesenteric lymph nodes may provide supportive information but is generally insufficient for definitive diagnosis of low-grade disease due to the well-differentiated nature of the neoplastic cells [4].

There is currently no curative treatment for feline small cell alimentary lymphoma; therapy is aimed at achieving and maintaining clinical remission and prolonging quality life [4][5].

Chemotherapy: Chlorambucil and Prednisolone (First-Line Standard of Care) The combination of chlorambucil (an alkylating agent) and prednisolone (a glucocorticoid) is the established first-line treatment protocol for LGAL and is associated with high response rates and prolonged survival [4][5]:

• ·Chlorambucil: Most commonly administered orally at 20 mg/m² every 2 weeks (pulse dosing), or alternatively at 2 mg/cat every 48–72 hours (continuous low-dose protocol). Both regimens have shown efficacy. The continuous low-dose protocol may be preferred in some patients or clinical settings.
• ·Prednisolone: Typically initiated at immunosuppressive doses (e.g., 1–2 mg/kg/day orally) and tapered over time based on response. Prednisolone is preferred over dexamethasone in cats due to better oral bioavailability.

Monitoring during chlorambucil therapy includes periodic CBC (every 4–8 weeks initially) to detect myelosuppression (leukopenia, thrombocytopenia), though significant bone marrow toxicity is less common at standard doses than with other cytotoxics [4].

Supportive Nutritional Therapy

• ·Cobalamin (Vitamin B12) supplementation: Strongly recommended in hypocobalaminemic cats; parenteral (subcutaneous cyanocobalamin) or oral supplementation is used to address malabsorption and support mucosal recovery
• ·High-digestibility or hydrolyzed protein diets: May benefit cats with concurrent food-responsive disease or to support overall gastrointestinal health
• ·Appetite stimulants: Mirtazapine (orally or transdermal) may be used in anorectic cats to support caloric intake

Antiemetics

• ·Maropitant (Cerenia®) and/or metoclopramide may be used to manage nausea and vomiting during active disease or chemotherapy

Management of Concurrent Conditions Many cats with LGAL are geriatric and may have concurrent hyperthyroidism, chronic kidney disease, or hepatic disease, all of which must be addressed and factored into treatment planning [4][5]. Hyperthyroidism, in particular, can mask weight loss attributable to LGAL.

Rescue / Second-Line Therapy For cats that relapse or fail first-line chlorambucil/prednisolone therapy, alternative protocols including lomustine (CCNU) or cyclophosphamide-based protocols may be considered, though evidence specifically in LGAL is more limited [4].

Surgery Surgery is generally not indicated for diffuse small cell lymphoma. It may be considered for management of focal complications such as intestinal perforation or obstruction, which are uncommon in the low-grade form [4].

Feline small cell / low-grade alimentary lymphoma carries a significantly more favorable prognosis compared to high-grade (large cell) alimentary lymphoma, and many cats achieve prolonged clinical remission with appropriate therapy [4][5].

Response Rates The majority of cats with LGAL respond to chlorambucil and prednisolone therapy. Response rates in the literature have been reported as high as approximately 70–96% depending on the study design and response criteria used [4]. Clinical remission (resolution or substantial reduction in clinical signs) is achievable in most treated cats.

Survival Times

• ·Median survival times reported for cats with LGAL treated with chlorambucil and prednisolone range from approximately 704 days to over 800 days (approximately 2–2.5 years) in multiple published series [4][5].
• ·Some cats achieve long-term remission extending beyond 3–4 years.
• ·Cats that achieve complete clinical remission tend to have significantly longer survival times than partial responders.

Prognostic Factors

• ·Serum albumin: Hypoalbuminemia at diagnosis has been associated with poorer outcomes [1]
• ·Degree of weight loss at presentation: More severe cachexia is associated with worse prognosis
• ·Concurrent diseases: The presence of concurrent conditions (CKD, hyperthyroidism, cardiac disease) in this predominantly geriatric population may limit treatment options and overall prognosis independent of lymphoma response
• ·Completeness of staging: Cats with disease limited to the small intestine vs. those with more widespread gastrointestinal involvement may have differing outcomes

Comparison with High-Grade Lymphoma In contrast, high-grade (large cell) alimentary lymphoma carries a median survival time of approximately 1.5–3 months even with aggressive multi-agent chemotherapy, underscoring the critical importance of accurate subtype classification [4].

Mortality Context While LGAL is ultimately a fatal malignancy in most cats, the disease course is typically indolent, and most cats die from or are euthanized due to progression of lymphoma or complications of concurrent geriatric diseases rather than acute lymphoma-associated crises. The disease is not acutely fatal in the short term for most patients, but long-term mortality approaches 100% given the incurable nature of the neoplasm.

There is currently no established, evidence-based preventive strategy specifically for feline small cell alimentary lymphoma [3][5].

Absence of Vaccines No vaccine exists for LGAL, as the disease is a primary neoplasm of T-lymphocyte origin rather than an infectious disease [4].

Microbiome Health Emerging research highlights the role of intestinal microbiome dysbiosis and altered tryptophan catabolism in the pathogenesis of LGITL [6]. While not yet translated into specific preventive recommendations, supporting gut microbiome health through appropriate diet, avoiding unnecessary antibiotics, and managing chronic gastrointestinal inflammation may theoretically be beneficial. Probiotic supplementation is occasionally recommended by clinicians to support gut health, though direct evidence of prevention of LGAL is lacking.

Early Identification and Management of Chronic Enteropathy Given the proposed continuum between chronic intestinal inflammation (IBD/LPE) and LGAL, early diagnosis and appropriate management of chronic inflammatory enteropathies may theoretically reduce the risk of neoplastic transformation [5]. Cats with chronic, refractory gastrointestinal signs should receive thorough workup to differentiate inflammatory from neoplastic disease rather than receiving prolonged empirical treatment without diagnosis.

Routine Veterinary Monitoring Regular veterinary examinations for middle-aged and senior cats (>7–8 years of age), including physical examination, body weight monitoring, and baseline laboratory assessments, support early detection of weight loss, hypoalbuminemia, or other early indicators of gastrointestinal disease. Early detection and diagnosis generally enable more effective treatment and better quality of life [1][4].

FeLV Prevention While high-grade alimentary lymphoma has a historical association with FeLV infection, low-grade small cell lymphoma is not strongly FeLV-associated. Nevertheless, maintaining FeLV vaccination and minimizing FeLV exposure (indoor lifestyle, testing of new cats) remains appropriate for overall feline health [4].

References: [1] Freiche V. et al., J Vet Intern Med, 2021 — Clinical, laboratory and ultrasonographic findings differentiating LGITL from LPE in cats. [2] Freiche V. et al., J Vet Intern Med, 2021 — Histopathologic, phenotypic, and molecular criteria to discriminate LGITL from LPE in cats. [3] Paulin M. et al., BMC Vet Res, 2018 — Feline low-grade alimentary lymphoma: an emerging entity and potential animal model. [4] Wilson H., Top Companion Anim Med, 2008 — Feline alimentary lymphoma: demystifying the enigma. [5] Webb C. et al., Vet Clin North Am Small Anim Pract, 2026 — Navigating the diagnostic continuum: feline LPE and LGITL. [6] Barko P. et al., Animals (Basel), 2023 — Altered microbial tryptophan catabolism in feline CIE and LGITL. [7] Yu J. et al., J Vet Intern Med, 2023 — Serum proteome profiles in cats with chronic enteropathies. [8] Chino J. et al., J Vet Med Sci, 2013 — Cytomorphological and immunological classification of feline lymphomas.